Eli Lilly Says It Doesn’t Have to Provide 340B-Priced Drugs to Contract Pharmacies

A note from Publisher and CEO Ted Slafsky: Our sponsors are 340B’s industry leaders and we are proud to showcase their innovative solutions and guidance to help you implement and comply with this complex program. Click on the button

Read More »

340B Drug Manufacturer Audits: A Q&A with HRSA


A note from 340B Report CEO and Publisher Ted Slafsky: Please join us in welcoming Comprehensive Pharmacy Services to our growing group of 340B Report sponsors! And I hope you enjoy a new column from

Read More »

HRSA Takes Step to Improve 340B Pricing Consistency


A note from 340B Report CEO and Publisher Ted Slafsky: I encourage all of you to read Trellis Rx Chief Pharmacy Officer Jerry Buller’s great article in today’s issue about how 340B health systems can leverage

Read More »

DOJ Says Mallinckrodt Owes Medicaid Hundreds of Millions in Rebates, but Is Silent About 340B Overcharges

DOJ Says Mallinckrodt Owes Medicaid Hundreds of Millions in Rebates, but Is Silent About 340B Overcharges

The U.S. Justice Department is suing drug manufacturer Mallinckrodt for allegedly

Read More »

340B Providers Could Face Drug Access Challenges Due to Coronavirus

340B Providers Could Face Drug Access Challenges Due to Coronavirus

In theory, federal law and 340B program guidance should protect 340B entities from shouldering an unfair

Read More »

Drugmakers Are Doing a Better Job of Supplying 340B Ceiling Price Data, 340B Program Head Pedley Says

Drug manufacturers are doing a better job of providing the Health Resources and Services Administration (HRSA) with timely and accurate data needed to verify their 340B ceiling prices, the head of the federal 340B drug pricing program indicated today. Nonetheless,

Read More »

President Expected to Address Drug Prices in State of the Union Message

President Expected to Address Drug Prices in State of the Union Message

In his State of the Union address tonight, President Trump is expected to announce an initiative to make insulin more affordable and to challenge Congress to pass legislation

Read More »

Breaking News

BREAKING: Drugmaker Xspire Owes 340B Refunds

Greetings

Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news.

BREAKING: Drugmaker Xspire Owes 340B Refunds

Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live